Loading stock data…
NCNA
$2.25+0.11 (+5.14%)
Market ClosedLast close May 1
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NuCana plc in the Healthcare sector is trading at $2.25. The stock is currently near its 52-week low of $1.33, remaining 39.8% below its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why NCNA maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.25
Potential Downside
100%
Whystock Fair Value$0.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.80
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-125.24%
Volume
Today's trading volume
28,043
Recent News
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
European equities traded in the US as American depositary receipts were trending lower late Monday m
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
European equities traded in the US as American depositary receipts were rising late Friday morning,
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Tuesday Trading
European equities traded in the US as American depositary receipts were falling sharply late Tuesday
European Equities Traded in the US as American Depositary Receipts Sharply Higher in Friday Trading
European equities traded in the US as American depositary receipts were climbing higher late Friday
European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading
European equities traded in the US as American depositary receipts were trending lower late Thursday